4 registrations that name lutein and zeaxanthin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
3US sites across 3 states
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT06489873
Lutein, Zeaxathin, and Fish Oil Supplementation
No phase
Texas A&M University
About 80 people
Started Feb 7, 2024
In plain words A study of lutein and zeaxanthin in people 18 to 45, run by Texas A&M University. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Cognitive Performance; Age-Related Macular Degeneration; Bone Loss.
<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.
The exclusion criteria are on the listing.
What it tests, as registered
Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF); Placebo Comparator
Registered summary
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05232409
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Phase 1
Valley Health System
About 72 people
Started Apr 17, 2022
In plain words A Phase 1 study of lutein and zeaxanthin in people 18 to 99, run by Valley Health System. It plans to enroll about 72 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99. Conditions: Cancer Metastatic; Metastatic Solid Tumor.
Stage IV or unresectable stage 3 histologically confirmed solid tumor malignancy refractory to all standard therapies known to provide clinical benefit (unless the therapy is contraindicated or intolerable) in the opinion of the treating…
Age ≥ 18 years.
Performance status ECOG 0, 1 or 2
Adequate organ and marrow function as describe below:
13 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Zeaxanthin; Zeaxanthin Plus Pembrolizumab
Registered summary
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Where, as registered
1 US site in 1 state.
RecruitingNCT06965426
Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
No phase
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
About 60 people
Started Jun 1, 2025
In plain words A study of lutein and zeaxanthin in people 18 and older, run by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Macular Degenerative Disease.
Adult patients 18-50 years old of any sex and any race.
Willing to comply with the protocol instructions.
Has read (or has had read to), understood, and signed an Informed Consent.
The exclusion criteria are on the listing.
What it tests, as registered
Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
Registered summary
To compare skin carotenoid scores over 12 weeks of individuals randomized to placebo or MacuHealth and comparing that to a 12 week crossover evaluation.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07600567
Algal Lutein Against Decline of Intellectual Nimbleness
No phase
Poznan University of Life Sciences
About 300 people
Starts May 1, 2026 (estimated)
In plain words A study of lutein and zeaxanthin in female participants 48 to 60, run by Poznan University of Life Sciences. It plans to enroll about 300 people at 1 site, none in the US.
Postmenopausal status (natural menopause, up to 5 years after menopause)
waist circumference ≥ 88 cm
The exclusion criteria are on the listing.
What it tests, as registered
Lutein; Placebo
Registered summary
Lutein is a xanthophyll pigment found in photosynthesizing organisms. Its beneficial effects on health, including brain function and visual performance, have been recognized for many years. However, to date, only a limited number of well-designed human intervention studies have been published regarding the effects of incorporating lutein into the daily diet (as humans are unable to synthesize lutein endogenously). The full summary is on the listing.
Where, as registered
No US site; Poland (1).
ClinicalTrials.gov lists 12 open registrations for this search, including ones where lutein and zeaxanthin is not a study arm or that are past the 4 we keep. Search them on ClinicalTrials.gov (opens in new tab).